These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9392332)

  • 1. Analysis of bcl-2 in sporadic breast carcinoma.
    Dueñas-González A; Abad-Hernández MM; Cruz-Hernández JJ; González-Sarmiento R
    Cancer; 1997 Dec; 80(11):2100-8. PubMed ID: 9392332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma.
    Niemhom S; Kitazawa S; Murao S; Kunachak S; Maeda S
    Cancer Lett; 2000 Nov; 160(2):199-208. PubMed ID: 11053650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression of bcl-2 in Brca1-associated breast cancers.
    Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
    Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma.
    Pezeshki AM; Farjadian S; Talei A; Vasei M; Gharesi-Fard B; Doroudchi M; Ghaderi A
    Cancer Lett; 2001 Aug; 169(1):69-75. PubMed ID: 11410327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast.
    Megha T; Ferrari F; Arcuri F; Lalinga AV; Lazzi S; Cardone C; Cevenini G; Leoncini L; Tosi P
    Oncol Rep; 2000; 7(3):473-8. PubMed ID: 10767354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
    Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
    J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.
    Fricke E; Keller G; Becker I; Rosivatz E; Schott C; Plaschke S; Rudelius M; Hermannstädter C; Busch R; Höfler H; Becker KF; Luber B
    Int J Cancer; 2003 Mar; 104(1):60-5. PubMed ID: 12532420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene.
    Sturm I; Papadopoulos S; Hillebrand T; Benter T; Lück HJ; Wolff G; Dörken B; Daniel PT
    Int J Cancer; 2000 Aug; 87(4):517-21. PubMed ID: 10918191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant inactivation of p53 and Chk2 in breast cancer.
    Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
    Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of p53 and BAX mutations, loss of heterozygosity, p53 and BCL2 expression and apoptosis in basal cell carcinoma in Korean patients.
    Cho S; Hahm JH; Hong YS
    Br J Dermatol; 2001 Apr; 144(4):841-8. PubMed ID: 11298546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Seidal T
    Int J Gynecol Cancer; 2001; 11(2):147-58. PubMed ID: 11328414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
    Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
    Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53 and Bcl-2 in acute lymphoblastic leukemia.
    Sahu GR; Das BR
    Oncol Rep; 2002; 9(6):1391-8. PubMed ID: 12375054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection.
    Ye D; Li H; Qian S; Sun Y; Zheng J; Ma Y
    J Urol; 1998 Dec; 160(6 Pt 1):2025-8; discussion 2029. PubMed ID: 9817315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
    Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
    Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
    Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
    Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting p53 gene mutation of breast cancer and defining differences between silver staining PCR-SSCP and immunohistochemical staining.
    Ryu JW; Lee MC; Jang WC
    J Korean Med Sci; 2000 Feb; 15(1):73-7. PubMed ID: 10719813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.